SARS-CoV-2 Spike Protein RBD (Delta B.1.617.2 Variant) Neutralizing Antibody

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein RBD (Delta B.1.617.2 Variant) Neutralizing Antibody is a recombinant Human Monoclonal Antibody against SARS-CoV-2/COVID-19 Spike Protein RBD (Delta B.1.617.2 Variant).

The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.

The B.1.617.2 (Delta) variant was first identified in India. It contains the L452R and T478K mutations, which appear to increase viral infectivity compared with other variants.

Target	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD (Delta B.1.617.2 Variant)
Clonality	Monoclonal
Clone	Q220
Reactivity	Virus
Expression	Recombinant
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1
Form	Liquid
Purification	Purified by Protein A affinity chromatography.
Storage	Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles.
Buffer	PBS, pH 7.5.
Concentration	1 mg/ml
Availability	Shipped within 5-10 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD (Delta B.1.617.2 Variant)

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue